文献速递炎症性肠病

皮下英夫利西单抗(CT-P13 SC)作为炎症性肠病维持治疗:两项随机3期试验(LIBERTY)

Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY).
PubMed 文献 · Gastroenterology · 2024-05-23

两项随机、安慰剂对照、双盲3期试验评估CT-P13皮下制剂对中重度活动性克罗恩病(CD)和溃疡性结肠炎(UC)的维持治疗。患者先接受CT-P13静脉5 mg/kg开放诱导,第10周临床应答者按2:1随机接受CT-P13 SC 120 mg或安慰剂每2周至第54周。第54周CT-P13 SC组临床缓解和內镜应答率显著高于安慰剂,耐受性良好。

要点

  • CD第54周临床缓解率CT-P13 SC组62.3% vs 安慰剂组32.1%(P < .0001)。
  • CD第54周內镜应答率CT-P13 SC组51.1% vs 安慰剂组17.9%(P < .0001)。
  • UC第54周临床缓解率CT-P13 SC组43.2% vs 安慰剂组20.8%(P < .0001)。

核心结论

  • 对于CT-P13静脉诱导应答的中重度活动性CD或UC患者,CT-P13 SC维持治疗比安慰剂更有效且耐受性良好。

研究设计与样本

  • 两项随机、安慰剂对照、双盲3期研究,纳入对皮质类固醇和免疫调节剂应答不足或不耐受的中重度活动性CD或UC患者。
  • 所有患者在第0、2、6周接受开放标签CT-P13静脉5 mg/kg诱导;第10周临床应答者按2:1随机接受CT-P13 SC 120 mg或安慰剂每2周至第54周(维持期),使用预充式注射器。
  • CD研究共396例患者接受诱导治疗,UC研究共548例患者接受诱导治疗。
  • (共同)主要终点为第54周临床缓解和內镜应答(CD)及临床缓解(UC),基于全随机人群分析。

主要发现

  • CD研究第54周,CT-P13 SC组临床缓解率62.3% vs 安慰剂组32.1%(P < .0001),內镜应答率51.1% vs 17.9%(P < .0001)。
  • UC研究第54周,CT-P13 SC组临床缓解率43.2% vs 安慰剂组20.8%(P < .0001)。
  • 两项研究中,CT-P13 SC组关键次要终点的达标率均显著高于安慰剂组。
  • CT-P13 SC耐受性良好,未发现新的安全性信号。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: CT-P13 subcutaneous (SC), an SC formulation of the intravenous (IV) infliximab biosimilar CT-P13 IV, creates a unique exposure profile. The LIBERTY studies aimed to demonstrate superiority of CT-P13 SC vs placebo as maintenance therapy in patients with Crohn's disease (CD) and ulcerative colitis (UC). METHODS: Two randomized, placebo-controlled, double-blind studies were conducted in patients with moderately to severely active CD or UC and inadequate response or intolerance to corticosteroids and immunomodulators. All patients received open-label CT-P13 IV 5 mg/kg at weeks 0, 2, and 6. At week 10, clinical responders were randomized (2:1) to CT-P13 SC 120 mg or placebo every 2 weeks until week 54 (maintenance phase) using prefilled syringes. (Co-) primary end points were clinical remission and endoscopic response (CD) and clinical remission (UC) at week 54 (all-randomized population). RESULTS: Overall, 396 patients with CD and 548 patients with UC received induction treatment. At week 54 in the CD study, statistically significant higher proportions of CT-P13 SC-treated patients vs placebo-treated patients achieved clinical remission (62.3% vs 32.1%; P < .0001) and endoscopic response (51.1% vs 17.9%; P < .0001). In the UC study, clinical remission rates at week 54 were statistically significantly higher with CT-P13 SC vs placebo (43.2% vs 20.8%; P < .0001). Achievement of key secondary end points was significantly higher with CT-P13 SC vs placebo across both studies. CT-P13 SC was well tolerated, with no new safety signals identified. CONCLUSIONS: CT-P13 SC was more effective than placebo as maintenance therapy and was well tolerated in patients with moderately to severely active CD or UC who responded to CT-P13 IV induction. CLINICALTRIALS: gov, Numbers: NCT03945019 (CD) and NCT04205643 (UC).

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Hanauer SB, Sands BE, Schreiber S, et al. Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY). Gastroenterology. 2024. PMID: 38788861. doi:10.1053/j.gastro.2024.05.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。